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Many antibiotics available in the clinic today directly inhibit bacterial trans-
lation. Despite the past success of such drugs, their efficacy is diminishing
with the spread of antibiotic resistance. Through the use of ribosomal modifi-
cations, ribosomal protection proteins, translation elongation factors and
mistranslation, many pathogens are able to establish resistance to common
therapeutics. However, current efforts in drug discovery are focused on over-
coming these obstacles through the modification or discovery of new treatment
options. Here, we provide an overview for common mechanisms of resistance
to translation-targeting drugs and summarize several important breakthroughs
in recent drug development.
1. Introduction
Protein synthesis is an essential process that is required by all living organisms.
Through the process of translation, the ribosome reads a messenger RNA transcript
and synthesizes the encoded protein sequence. Although translation maintains
universal importance, there are distinct differences between eukaryotic and pro-
karyotic translation that have historically been exploited for the development of
antibiotics. When a bacterial pathogen is treated with a translation inhibitor,
protein synthesis rapidly halts, leading to death or severe growth limitation.
Current treatments inhibit translation through a variety of different strategies, ran-
ging from directly targeting the ribosome to targeting aminoacyl tRNA (aa-tRNA)
synthetases [1–5]. This method of treating infections has been so effective that
dozens of different translation inhibitors have been brought to the clinic since the
1940s, effectively revolutionizing healthcare [6,7]. With the development of anti-
biotics, an infection that was once life-threatening can now be cleared in a matter
of days. However, almost as quickly as these drugs have been developed, they
are also being rendered obsolete, as bacteria are rapidly acquiring and evolving
mechanisms of resistance in order to avoid eradication. Excessive and inappropri-
ate use of antibiotics has facilitated the rise and spread of multidrug-resistant
pathogens, commonly referred to as superbugs [6,8,9]. With the recent plateau in
discovery of new classes of antibiotics, infections that are currently treatable may
once again become deadly. Despite the looming threat of a post-antibiotic world,
efforts to develop new strategies to target translation leave us with an optimistic
outlook. Several recent reviews have presented an in-depth look at the mechanism
of action of antibiotics targeting translation and specific mutations that confer
resistance [1–3,5,10,11]. Here, we bring together the different points in translation
that can be targeted for antibiotic development in an overview of common trans-
lation drug targets, mechanisms of resistance, and exciting new directions in the
development of novel translation-targeting antibiotics.
2. Resistance formation
2.1. Modification of the ribosome
The ribosome is the central hub of protein production within the cell. Consisting
entirely of ribosomal RNA (rRNA) and proteins, the bacterial ribosome is
& 2019 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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composed of a large 50 S and small 30 S subunit (figure 1).
Due to the large and complex nature of the ribosome, its
activity can be inhibited by a variety of different methods
with antibiotics that bind in distinct locations [1–3]. For
example, aminoglycosides generally target the 30 S subunit,
preventing translocation or A-site tRNA binding and promot-
ing miscoding, while macrolides bind the nascent peptide
exit tunnel on the 50 S subunit, preventing peptide bond
formation and translocation (figure 1) [12,13]. Though both
classes of antibiotics maintain distinct activities, both are
efficient at halting translation. Modification of the ribosome
is one of the most direct forms of antibiotic resistance. Bac-
teria will often employ methyltransferases to methylate
either the large subunit 23 S or small subunit 16 S rRNA
[13–15]. Through this methylation, interactions that anti-
biotics made with either of these rRNAs are prevented, and
drug activity is inhibited. Although modification of the ribo-
some is effective in preventing antibiotic binding, it is not
necessarily without its limitations. Some ribosomal modifi-
cations alter translation and result in a fitness cost [16]. For
this reason, ribosomal modification is often inducible so
that it is only used when necessary for survival. For example,
erythromycin will induce ribosomal pausing on the leader
peptide for the methylase responsible for the dimethylation
of the 23 S rRNA, ermC [17]. This pausing induces the
transcript to form a structure in which the Shine–Dalgarno
sequence for ermC is exposed, allowing for the translation
of ermC [15,18,19]. ErmC then methylates the nascent peptide
exit tunnel and prevents erythromycin binding. This resist-
ance often comes with a cost, as strains of Staphylococcus
aureus that are engineered to constitutively express ermC are
outcompeted by wild-type strains due to the inefficient
translation of select polypeptides [16]. This inducible
system allows S. aureus to survive in the presence of an anti-
biotic yet still maintain optimal proteome homeostasis when
conditions are favourable.
For organisms that maintain numerous copies of rRNA
genes, rRNA methylation is an ideal mode of resistance, as
each ribosome can receive the modification without the
need to acquire the exact same mutation in each rRNA in
the genome. However, in organisms that maintain a rela-
tively low number of rRNA genes, copy number is no
longer a constraint to the development of resistance
mutations. For example, Mycobacterium tuberculosis only
maintains one copy of each rRNA, and mutation of nucleo-
tides within these rRNAs is an effective way to prevent
antibiotic activity. A single amino acid substitution,
A1408G, in the 16 S rRNA has been shown to decrease suscep-
tibility of M. tuberculosis to aminoglycosides through inhibition
of binding [20]. However, as was observed with methylation
of the 23 S or 16 S, this mutation comes with a considerable fit-
ness cost. To ameliorate the impact of A1408G, M. tuberculosis
has been shown to upregulate rRNA methyltransferase tlyA,
which will then methylate C1409 in the 16 S rRNA [20].
Although this modification does improve the overall fitness
of the pathogen, it does lessen the resistance conferred by
the A1408G mutation [20]. Through this trade-off, M. tubercu-
losis maintains a middle ground between optimal fitness and
effective resistance.
Unlike rRNAs, bacteria generally only maintain a single
copy of each ribosomal protein. These proteins can easily
acquire mutations to prevent antibiotic activity. For example,
mutations in the 30 S ribosomal subunit protein S12 have
been shown to induce resistance to miscoding antibiotics
such as paromomycin and streptomycin [21–23]. S12 plays
a critical role in ensuring the correct codon–anticodon pair
is made during decoding. Although identified mutations do
not prevent drug binding, they have been shown to signifi-
cantly increase ribosomal accuracy, effectively counteracting
drug activity [24]. In vitro, these mutations often also come
with a significant fitness cost, as this increase in fidelity
also decreases the rate of translation elongation [24,25]. How-
ever, second site compensatory mutations can ameliorate
this effect, and S12 mutations have also been identified
in vivo in M. tuberculosis that are virtually cost free [26–30].
This suggests that simply reducing antibiotic use will not
necessarily result in the elimination of resistant pathogens
through competition with the sensitive strains, as is
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Figure 1. General points of inhibition on the 70 S ribosome and discussed drugs that target them.
royalsocietypublishing.org/journal/rsob
Open
Biol.9:190051
2
commonly believed [26,27]. The gravity of this observation
highlights the need for future drug development.
2.2. Ribosomal protection proteins
While modification of the ribosome is effective, it generates
ribosomes that are not operating at maximum efficiency. As
an alternative method of prevention of antibiotic binding,
many bacteria employ ribosomal protection proteins (RPPs).
An RPP will inhibit drug activity without also permanently
altering ribosomal activity. Through direct, reversible binding
to the ribosome, several different RPPs have been identified
that can prevent drug binding or even dislodge drugs that
target either the 50 S or 30 S subunit (figure 2) [11,33].
Both TetM and TetO are RPPs that inhibit the activity of
tetracycline, an antibiotic that directly targets the 30 S subunit
and prevents aa-tRNA binding at the A site [11,34]. Structural
studies have indicated that the protection provided by these
proteins is twofold. First, TetM (or TetO) will bind and
induce a conformational change in the ribosome. This struc-
tural change disrupts key bonds between tetracycline and
the ribosome and dislodges it from its binding pocket
[31,35]. Second, this new conformation prevents the drug
from rebinding, further potentiating the protection [31,35].
Thus, through both of these activities, TetO and TetM are
effective in preventing tetracycline binding and removing
drug once bound (figure 2a). For a recent specialized review
on tetracycline resistance mechanisms, see Nguyen et al. [11].
A second class of RPPs is the antibiotic resistance (ARE)
ATP-binding Casette F (ABCF) proteins. ARE ABCFs are a
widespread family of proteins that have been shown to med-
iate resistance against a diverse set of 50 S targeting drugs.
Although they are named for their ability to bind and hydro-
lyse adenosine triphosphate (ATP), recent evidence indicates
they also hydrolyse other nucleotide triphosphates (NTPs)
[36]. On average, bacteria maintain four ABCFs per genome,
with the most being found in Firmicutes and Actinobacteria
[37]. Although the general activity of these proteins had
been known for some time, the precise mechanism of action
had been controversial. Until recently, there were competing
theories postulating that these proteins either associated with
a transmembrane domain and acted as efflux pumps, or that
they directly inhibited antibiotic activity as RPPs [33]. How-
ever, in vitro translation experiments provided strong
evidence for the latter theory, as addition of an ARE ABCF
protein to an in vitro translation assay prevented macrolide
inhibition of translation in a concentration-dependent
manner [38]. This was further solidified with the recent eluci-
dation of the structures of two ARE ABCF proteins, MsrE and
VmlR, bound to the 70 S ribosome [32,39]. From these struc-
tures, it was evident that these RPPs directly bind to the E-
site of the 50 S subunit. Upon binding, the linker domain
extends into the peptidyl transfer centre, inducing a confor-
mational change in the ribosome that will result in drug
release (figure 2b) [32,37,39]. Through these studies, the
scope of RPPs was significantly broadened to show that
this mechanism of resistance can be applied to the 50 S as
well as the 30 S subunit. For a recent specialized review on
ABCF-mediated ribosomal protection, see Ero et al. [10].
2.3. Translation factors
Although the ribosome is the central hub of protein synthesis,
it cannot function properly without the assistance of
additional translation factors. Translation factor elongation
factor G (EF-G) is an essential GTPase that catalyses tRNA
translocation through the ribosome. EF-G activity can be
directly or indirectly inhibited through the use of several
different drugs [40]. For example, fusidic acid binds directly
to EF-G and traps it by binding it to the ribosome [41].
Although this will efficiently halt translation, fusidic acid
resistance can be easily acquired through point mutations in
EF-G that alter drug activity [42]. Such mutations have
been identified in clinical isolates of S. aureus [42,43].
Although such mutations generally come with a fitness
cost, clinical isolates of S. aureus have been identified that
maintain both the resistance mutation and compensatory
mutations to reduce this cost [44]. To lower the rate of resist-
ance formation, fusidic acid is generally only used in a clinical
setting in combination with other drugs [43]. Ribosome bind-
ing drugs can also indirectly inhibit EF-G activity. Several
crystallography studies have found that thiopeptides,
GE82832 and dityromycin bind the ribosome and inhibit
EF-G-catalysed translocation [3,45]. However, resistance can
be acquired to these drugs through point mutations within
the ribosomal protein S12 that prevent drug binding [45].
In addition to EF-G, the ribosome also requires another
essential GTPase, elongation factor Tu (EF-Tu). EF-Tu binds
(a) (b)
50 S
E P A P A
TetM
VmlR
30 S 30 S
50 S
Figure 2. Ribosomal protection proteins bind the ribosome to dislodge inhibitory drugs and restore ribosome activity. (a) TetM binds the 16 S rRNA in the 30 S subunit
to dislodge tetracycline [31]. (b) VmlR binds the E site and extends into the peptidyl transfer center to dislodge 50 S targeting drugs such as steptogramin A or
lincosamides [32].
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aminoacylated tRNAs and escorts them to the A-site of the
ribosome. Upon codon–anticodon pairing, EF-Tu will hydro-
lyse guanosine triphosphate (GTP), release the aa-tRNA and
dissociate from the ribosome. Although EF-Tu plays a critical
role in translation elongation, drugs found to target EF-Tu
generally have low solubility and permeability and are not
amenable to clinical use [46]. However, further optimization
of such drugs could provide useful compounds in the
future. To date, over 30 EF-Tu inhibitors (also known as elfa-
mycins) have been identified [46]. EF-Tu activity can be
inhibited with drugs that will trap EF-Tu bound to the ribo-
some or with drugs that will prevent EF-Tu:GTP aa-tRNA
ternary complex formation [47–49]. Although resistance for-
mation against elfamycins has never been characterized in a
clinical setting, strides have been made to anticipate potential
mechanisms of resistance to such drugs. Given that many
bacteria maintain two copies of EF-Tu, elfamycin resistance
can be rather complicated. In the case of drugs that prevent
ternary complex formation, only one copy of EF-Tu needs
to acquire the resistance mutation to continue functioning
in translation [50]. In the case of drugs that trap EF-Tu on
the ribosome such as kirromycin, both copies of EF-Tu
would have to acquire resistance mutations, as a single
non-resistant EF-Tu will have a dominant effect due to
increased affinity. Resistance to kirromycin has only been
observed in bacterial strains in which one copy of EF-Tu
has been inactivated [51]. Although this makes elfamycins
an enticing lead in drug discovery, significant optimization
will be required to improve their pharmacokinetic proper-
ties before they are brought to the clinic [46]. For a recent
specialized review on elfamycins, see Prezioso et al. [46].
2.4. Mistranslation-mediated resistance
During translation, the ribosome must correctly pair each
codon with the corresponding aminoacylated tRNA so that
the appropriate amino acid will be incorporated into the nas-
cent peptide chain. Although accuracy in this process is
critical for maintaining the fidelity of the genetic code,
errors in translation have been estimated to be as high as
1024 per codon [52,53]. These errors in translation are com-
monly referred to as mistranslation and have been shown to
influence antibiotic resistance in a number of different ways.
First, mutations in ribosomal proteins can have a
significant impact on ribosome activity, often enhancing or
diminishing decoding accuracy depending on the location
of the mutation [54]. For example, it has previously been
observed that mutations in ribosomal protein RpsD result
in a marked increase in the rate of mistranslation [53,55,56].
Although strains harbouring this mutation generally exhibit
a decrease in fitness due to the high number of errors in
their proteome, these errors can be advantageous for the
population as a whole when confronted with cefotaxime
[54]. In the presence of low levels of this drug, weakly dele-
terious mutations in the cefotaxime resistance protein
(TEM-1) are tolerated (figure 3). Although such a mutation
would not be beneficial, when the concentration of the anti-
biotic is low, the fitness cost associated with the mutation is
not significant enough to result in complete elimination of
the organism. However, if the organism maintains a high
level of mistranslation, then the TEM-1 can harbour both
this weakly deleterious mutation as well as mistranslated
residues. This combination exacerbates the deleterious effects
of the mutation, and it is effectively purged from the popu-
lation, resulting in enhanced fitness overall (figure 3) [54].
In this way, mistranslation can be advantageous to a popu-
lation that is met with an antibiotic stress. However, it is
noteworthy that this effect is only observed in the presence
of low levels of antibiotic, where organisms with weakly
deleterious mutations are able to survive. When the antibiotic
stress is high enough, even weakly deleterious mutations in
an antibiotic-resistance gene cannot be tolerated. Although
this suggests that this phenomenon would not be relevant
in a patient being treated with a high dose of an antibiotic,
it could be critical for the survival of resistant pathogens in
the environment. With the inappropriate and overuse of anti-
biotics, low levels of these drugs make their way into the
environment [6]. Within this context, it is likely that mistran-
slation could aid in enhancing fitness of organisms that are
tolerating this low level of antibiotic stress.
A second source of mistranslation arises from errors in
aminoacylation of tRNAs. Aminoacyl tRNA synthetases
(aaRSs) are the enzymes responsible for correctly pairing
each tRNA to its cognate amino acid. Errors in this process
can result in misacylated tRNAs that are then used for trans-
lation, allowing non-cognate amino acids to be incorporated
into a protein. Mutation of aaRSs and related proteins can
disrupt the fidelity of aminoacylation and allow for mistransla-
tion. Such mutations have often been found in clinical isolates
that display enhanced antibiotic resistance. For example,
clinical isolates of M. tuberculosis have been shown to harbour
mutations in gatA, an amidotransferase that facilitates the
conversion of Glu-tRNAGln to Gln-tRNAGln and Asp-tRNAAsn
to Asn-tRNAAsn [57]. These mutations in gatA result in an
increase in misincorporation of Glu at Gln codons and Asp
at Asn codons. Through such misincorporation, an Asn
residue in RpoB that is critical for rifampicin binding is mis-
translated as an Asp. This substitution prevents rifampicin
binding and makes M. tuberculosis highly tolerant of rifampicin
treatment [57,58].
Mutations in aaRSs have also been shown to influence
antibiotic resistance through indirect effects. For example,
strains that are resistant to ciprofloxacin often harbour
mutation
no mutation
weakly deleterious
mutation
weakly deleterious
mutation
+
mistranslated
residue
survival
Figure 3. Mistranslation exacerbates deleterious mutations in antibiotic-resist-
ance factors. An antibiotic-resistance protein (blue) with mutation (red X) can
maintain partial activity, and bacteria with such a mutation survive in the pres-
ence of low levels of antibiotic. Activity is lost when protein maintains both the
mutation and an additional mistranslated residue (yellow X), and the bacteria
die in the presence of low levels of antibiotic.
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mutations in several different aaRSs [59]. These mutations
result in inappropriate activation of the stringent response,
presumably through the accumulation of deacylated tRNAs.
Through the stringent response, the cell activates a number
of efflux pumps, which remove the antibiotic from the cell.
Although these mutations were initially identified in the pres-
ence of ciprofloxacin, activation of the stringent response
through aaRS inhibition was also shown to increase resistance
to drugs that act through diverse mechanisms including
rifampicin, chloramphenicol, mecillinam, ampicillin and
trimethoprim, indicating that partial aaRS inactivation can
have broad implications for resistance formation [59]. Escherichia
coli clinical isolates have also been identified that harbour
similar aaRS mutations, indicating that this mechanism is
likely relevant in vivo [60–63].
3. New frontiers in antibiotic development
Mechanisms of resistance have been identified for nearly
every translation inhibitor in the clinic [6]. As many of
these drugs are being inappropriately overused, resistance
will likely continue to spread until these drugs become obso-
lete [6,8,9]. This ominous threat merits the development of
new treatment options. Given the past success of translation
inhibitors as therapeutics, many are developing new strategies
to target this process. Currently, approximately one-third of
new drugs under clinical development target translation
(figure 4) [64].
3.1. Discovery of novel antibiotics
The years between 1940 and 1960 were the golden age of anti-
biotic development [6]. During this time, the majority of the
antibiotics used today were identified in soil-dwelling actino-
mycetes. However, as only 1% of bacteria can be cultured in a
laboratory setting, the number of compounds identified from
these organisms is limited [65]. After this short 20-year span,
screening cultivable actinomycetes for drugs was only lead-
ing to rediscovery of known compounds. This roadblock
was a major factor behind the plateau in antibiotic develop-
ment. However, in recent years, scientists have begun to
revisit this approach. Within previously unculturable organ-
isms, several promising new antibiotics have been identified.
Actinomycetes maintain a high number of non-ribosomal
peptide synthetases (NRPSs) and polyketide synthetases
(PKSs) that allow for the production of diverse metabolites
and antibiotics. Due to the previous success in identifying
drugs in actinomycetes, it is likely that other organisms that
maintain genes with similar functions will also produce
useful compounds. Like actinomycetes, the Xenorhabdus
genus maintains a relatively high number of diverse NRPSs
and PKSs [66]. However, Xenorhabdus is not typically used
for antibiotic discovery, as it is naturally a symbiont in soil-
dwelling nematodes. In a recent screen for antimicrobial
activity in Xenorhabdus extracts, a novel class of translation-
targeting antibiotics was identified. Odilorhabdin binds the
30 S ribosomal subunit at the decoding centre and induces
ribosomal stalling and miscoding, presumably through
increasing affinity of non-cognate aa-tRNAs for the A-site
[67]. Though this activity is reminiscent of aminoglycoside,
tetracycline and negamycin inhibition, the binding site of odi-
lorhabdin does not overlap with any of these drugs [67].
Further, odilorhabdin displays antimicrobial activity for a
wide spectrum of both Gram-positive and Gram-negative
pathogens while exhibiting low levels of toxicity in a murine
model, indicating odilorhabdin has a promising future as the
basis for new therapeutics [67].
Attempts have also been made to identify drugs in the
other 99% of bacteria that have never been cultured. Through
the use of isolation chips (iChips), scientists can now culture
bacteria directly in a soil environment, allowing for the
identification and characterization of previously uncultured
organisms [68]. New antibiotics can then be identified in
the extracts of these elusive organisms. For example, through
the use of iChips, teixobactin, a cell wall biosynthesis inhibi-
tor, was identified in Eleftheria terrae, an organism that was
previously uncultivable [69]. Although teixobactin does not
inhibit translation, this discovery highlights the potential for
discovery of novel translation-targeting drugs in previously
uncultured organisms.
3.2. Modification of existing antibiotics
Although the isolation of antibiotics from natural sources is a
relatively new development in modern medicine, these drugs
and the corresponding resistance genes are ancient [70–72].
Over millions of years, bacteria have evolved these compounds
and protection mechanisms for competition, communication
and regulation of gene expression. Isolation of previously
existing natural compounds comes with both significant
benefit and cost. On the one hand, the drugs that are being
isolated are the result of millions of years of evolution and
are therefore highly effective. On the other hand, the genes
that are required for resistance have also been selected for
over evolutionary time and can easily spread between organ-
isms in the presence of sufficient selective pressure. In an
effort to still use these potent antibiotics while avoiding
resistance mechanisms, drug development is turning to the
chemical modification of previously isolated compounds.
The modification of tetracycline has resulted in several ami-
nomethylcyclines and fluorocyclines that are currently under
clinical development or that have recently been approved by
the US Food and Drug Administration (FDA) [64]. The amino-
methylcycline omadacycline was FDA approved in 2018 to
treat community-acquired bacterial pneumonia and acute bac-
terial skin and skin structure infections and KBP-7072 (another
aminomethylcycline) is in clinical development for the treat-
ment of pneumonia and is effective against S. aureus and
Streptococcus pneumoniae in a murine model [64,73]. Of the
translation
cell wall
DNA replication
cell membrane
fatty acid biosynthesis
folate biosynthesis
cell division
Figure 4. Cellular targets of antibiotics currently under clinical development
based on analysis from the PEW Charitable Trusts [64].
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fluorocyclines, TP-271, TP-6076 and eravacycline have dis-
played potent in vivo efficacy, and eravacycline was FDA
approved in 2018 [64,74–78]. These drugs have also been
shown to be effective in vitro against tetracycline-resistant clini-
cal isolates, including isolates that are known to maintain
ribosomal protection proteins [76,78]. This indicates that
these modified drugs have the potential to avoid existing
resistance mechanisms.
Aminoglycosides have also been used as a scaffold for
chemical modification to generate more powerful antibiotics.
Plazomicin (ACHN-490) is a modified aminoglycoside that
was FDA approved in 2018 [64,79]. It is effective against
drug-resistant clinical isolates, including strains that are
known to be resistant to aminogyclosides and carabapenem-
resistant Enterobacteriaceae, which have been identified by
the Centers for Disease Control as an urgent threat in the
rise of antibiotic-resistant pathogens [79,80]. However,
plazomicin was not effective in vitro against strains expres-
sing 16 S methylase armA, indicating that it is not immune
to all modes of aminoglycoside resistance [79]. Attempts
have also been made to use aminoglycosides as carriers
that will target a ‘catalytic warhead’ directly to the ribosome.
Neomycin can be modified with diverse diamine compounds
that have been shown to accelerate the cleavage of
adenylyl(30 –50)adenosine [81]. It would be expected that, as
this modified neomycin binds the ribosome, the diamine
would stimulate cleavage of the 16 S rRNA, permanently dis-
abling the ribosome. Although initial results do not reveal
rRNA cleavage, structural data indicate that two diamine
modifications do induce a significant structural change in
the phosphate backbone of the 16 S rRNA [81]. Though this
change is not sufficient to stimulate rRNA cleavage, this
result indicates that, through remodelling of the diamine
modification, these warheads will be effective in disabling
ribosomes.
Synthetically derived ketolides are a promising class of
antibiotics that are currently under clinical development
[64,82,83]. Nafithromycin (WCK 4873) and solithromycin
(T-4288) are effective against a wide range of pathogens,
including some that are known to be resistant to macrolides
[84–86]. Although a recent metanalysis indicated that such
ketolides are not necessarily more potent than current treat-
ments, these drugs are believed to not fully induce
expression of the corresponding resistance gene and are
therefore powerful alternatives to avoid this mechanism
[84,87]. That being said, such drugs are less effective against
strains that display a constitutive macrolide–lincosamide–
streptogramin B-resistance phenotype [84,86]. It is important
to also note that ketolides could come with additional
limitations. Although all of the clinically relevant ketolides
are chemically derived from macrolides, a single naturally
occurring ketolide, pikromycin, has been isolated from Strep-
tomyces venezuelae [88]. In order to resist inhibition from the
pikromycin it produces, S. venezuelae must also maintain
two inducible methyltransferases ( pikR1 and pikR2) that pro-
vide resistance to this drug. Despite the diversity of the
synthetically derived ketolides, bacteria that have acquired
pikR1 or pikR2 become resistant to the synthetic compounds,
suggesting that chemically derived compounds are not
immune to all resistance mechanisms [88].
Recently, strides have also been made in the modification of
chloramphenicol, a phenicol that binds to the petidyl transfer-
ase centre and inhibits accommodation of the A-site aa-tRNA
(figure 1) [89,90]. Aminoacyl derivatives of chloramphenicol
have been shown to display both an increased affinity for the
ribosome and an altered drug binding site [89]. Owing to
this change in site specificity, structural data suggest that
these derivatives would not be inhibited by methylation of
the 23 S rRNA, a common resistance mechanism against pheni-
cols. However, these analogues do not display the same level of
translation inhibition as the parent molecule [89]. Further
chemical optimization would be required for these modified
compounds to be useful in a clinical setting. Derivatization of
chloramphenicol can also have a significant impact on which
cellular process the drug will target. For example, chloramphe-
nicol-derived enone and enal analogues have been shown to
inhibit cell wall biosynthesis rather than translation [90].
Although these derivatives have a drastically different mechan-
ism of action, they are still highly efficient in inhibiting bacterial
growth and exhibit a significantly lower propensity for
resistance formation than the parent molecule. Despite these
advantages, these analogues will also require more optim-
ization before they are ready for a clinical setting, as they
display high levels of toxicity in mammalian cell lines [90].
Many groups are taking the chemical modification of
drugs a step further by creating hybrid compounds that
merge two existing drugs with distinct mechanisms of
action. For example, MCB3837 (DNV3837) is an oxazolidi-
none/quinolone hybrid that is under clinical development
for the treatment of Clostridium difficile [64]. MCB3837 is
converted to MCB3681 upon intravaneous infusion, and
MCB3681 has been shown in vitro to have a lower minimum
inhibitory concentration (MIC) than cadazolid, fidaxomicin,
metronidazole and vancomycin against C. difficile clinical iso-
lates [91]. As C. difficile is an opportunistic pathogen that
colonizes as other bacteria are depleted, significant efforts
have been made to analyse changes in the microbiome in
response to MCB3837 treatment [92]. In proof-of-principle
human trials, MCB3837 had no significant impact on the
levels of resident Gram-negative bacteria in the human
skin, nose, oropharynx and intenstine microbiome, but
there was a significant reduction in clostridia, bifidobacteria,
lactobacilli, enterococci and S. aureus levels, indicating that
MC3837 does alter Gram-positive colonization, and could
be effective against C. difficile in the clinic [93,94].
3.3. Using translation for developing adjuvants
As a considerable amount of time and resources have gone
into the development of drugs currently in the clinic, it
would be desirable to prevent these treatments from becoming
obsolete. An alternative to complete drug redesign is to
identify compounds that can be used to potentiate current
treatments. Such additive therapies are referred to as adju-
vants, and they present several advantages in the future of
drug development. Adjuvants have the potential to broaden
the use of existing drugs and directly overcome resistance
mechanisms. As many adjuvant therapies in development
do not impact viability, they are often able to achieve this with-
out generating significant selective pressure for resistance
formation [95]. Several new strategies are under development
to look for adjuvants that will potentiate translation inhibitors.
One strategy in adjuvant development is to identify com-
pounds that will make existing drugs more effective against a
broader spectrum of bacteria. Many large, hydrophobic
translation-targeting drugs are ineffective against Gram-
royalsocietypublishing.org/journal/rsob
Open
Biol.9:190051
6
negative organisms, as they maintain an additional outer
membrane that prevents penetration of such drugs [96–99].
This barrier has resulted in fewer treatments available for
Gram-negative infections [65,96]. Many groups have used
high-throughput screening to look to adjuvant treatments
that sensitize the Gram-negative outer membrane to broaden
the scope of available treatments for such infections.
Polymyxin B non-apeptide (PMBN), pentamidine and oligo-
acyl-lysyls (OAKs) are small molecules that permeabilize
the Gram-negative outer membrane and allow for more effi-
cient penetration of translation inhibitors that are currently
only used to treat Gram-positive infections [96,100–103].
Although these treatments are not available in the clinic,
they have shown promise in vitro against clinical isolates
and in murine and Galleria mellonella infection models
[96,100–103]. For example, PMBN with erythromycin and
OAK with rifampicin combination therapies improve mouse
survival after Klebsiella pneumoniae infection [100,103]. Such
adjuvants have the potential to broaden the scope of patho-
gens that can be cleared with drugs that are already FDA
approved [102].
An alternative strategy in adjuvant development is to
identify drugs that directly inhibit resistance factors. For
example, resistance to aminoglycosides is often conferred
by aminoglycoside-modifying enzymes (AMEs) that inacti-
vate aminoglycosides with the addition of an acetylation or
phosphorylation [104]. Several groups have made strides
towards identifying AME inhibitors. Aminoglycoside bisub-
strates and cationic antimicrobial peptides have been shown
to directly inhibit AMEs in vitro, and several aminoglycoside
bisubstrates also have been shown to potentiate kanamycin
against Enterococcus faecium [105–108]. Inhibitors of the
acetyltransferase Eis (enhanced intracellular survival) also
potentiate kanamycin against M. tuberculosis [109]. In a simi-
lar strategy, enzymes that modify the ribosome can also
be directly targeted for adjuvant development. Several
groups have designed in silico or in vitro high-throughput
screens to identify compounds that target 23 S methylase
ErmC and prevent interactions with either the substrate
RNA or S-adenosyl-L-methionine [110–112]. E. coli expres-
sing ErmC are sensitized to erythromycin when co-treated
with such compounds [110,111]. ErmC inhibitors also lower
the azithromycin MIC for S. aureus, E. coli and Enterococcus
faecalis in vitro, but this result was not supported in a
murine model [112].
Pathogens have also been shown to use mistranslation as
a mode of resistance by altering target residues and prevent
antibiotic binding. In one of the aforementioned examples,
M. tuberculosis relies on the mistranslation of RpoB to prevent
rifampicin binding [57,58]. For this reason, preventing mis-
translation in M. tuberculosis is an attractive target for
developing an adjuvant therapy to potentiate rifampicin
treatment. As kasugamycin has previously been shown to
increase ribosomal accuracy, it is an intriguing candidate
for such a therapy. It has been demonstrated that kasugamy-
cin does in fact increase susceptibility of mycobacteria to
rifampicin both in vitro and in vivo [113]. However, the com-
bination of the drugs is poorly tolerated in a murine model
system and therefore unlikely to be a viable option in a clini-
cal setting [113]. Although kasugamycin specifically may not
be appropriate for patients, this example highlights the
potential for new drugs that alter translational accuracy to
be used as adjuvant therapies.
Bacterial translation can also be directly targeted in adju-
vant development. Elongation factor P (EF-P) is a universally
conserved translation factor that is required for efficient trans-
lation of polyproline motifs [114,115]. Although EF-P has
the same functional role in all bacteria characterized thus
far, the relative importance of EF-P in maintaining cellular
physiology varies between different organisms [116–123].
Despite the clear differences in the physiological significance
of EF-P, one unifying feature remains: antibiotic sensitivity.
Although it does not directly inhibit drug activity, EF-P has
repeatedly been shown to establish antibiotic resistance in
diverse pathogenic and non-pathogenic bacteria [119,121,123].
It is noteworthy that efp mutants are hypersensitive to
drugs with diverse mechanisms of action. For example,
a Salmonella enterica efp mutant displays increased suscepti-
bility to polymyxin B, a cell wall biosynthesis inhibitor, as
well as gentamicin, an aminoglycoside targeting the 30 S sub-
unit of the ribosome [119]. It is also important to note that,
although EF-P is required to maintain proteome homeostasis
and full antibiotic resistance, this impact is limited to con-
ditions of rapid growth. Recent evidence indicates that EF-P
activity is dispensable under conditions that induce slow
growth such as low temperatures and nutrient limitation, pre-
sumably due to decreased translational demands [124].
Therefore, the antibiotic hypersusceptibility observed in an
efp mutant is abolished when growth of the pathogen is
slowed. Given that a pathogen must undergo rapid proteo-
mic reprogramming as it adapts to survive in various cell
types within a host, within the context of infection, the role
of EF-P in facilitating antibiotic resistance is highly relevant
[125]. Though, it would likely lose this relevance in the
case of dormant persistors. This variability in the require-
ment for EF-P highlights the potential for culture
conditions to influence our interpretation of resistance for-
mation and drug discovery. For any infection, the
pathogen is not present as a pure culture, but rather a
single player within the vast human microbiome. Such
different environmental conditions can have a significant
impact on the relevance of any one translation factor and
should be considered in future work.
4. Conclusion
Bacterial translation has been successfully exploited for the
development of powerful antibiotics. Though they maintain
diverse mechanisms of action, translation inhibitors have
been used in the treatment of a wide variety of infections
and saved countless lives. However, with the rise and
spread of antibiotic-resistant pathogens, these treatments
are being rendered obsolete [6,7]. This threat is rapidly
becoming a global health crisis, resulting in tens of thousands
of deaths and billions of dollars in added healthcare costs.
Although scientists have made significant strides in the
fight against antibiotic resistance with translation inhibitors,
targeting translation comes with limitations. Translation is
an essential process, and inhibition of any process required
for viability creates immense selective pressure. Only patho-
gens that have evolved or acquired resistance are able to
survive, and they are able to thrive as non-resistant competi-
tors are eliminated. Furthermore, as translation is equally
important for the host’s beneficial microbiome, translation
inhibitors can have undesirable side effects. Development of
new drugs that do not impose such a strong selective
royalsocietypublishing.org/journal/rsob
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pressure will be a significant challenge. An additional
problem in the future of drug development will be overcom-
ing persistence, a dormancy state that allows bacteria to
survive in the presence of an antibiotic and then resume
growth after treatment. Persistence is particularly proble-
matic in a clinical setting, as it has been shown to increase
the likelihood of antibiotic-resistance formation and trans-
lation inhibitors are ineffective against such pathogens
[126]. Despite these challenges in drug development, trans-
lation inhibitors have proven to be effective therapeutics in
many settings. With new strategies in antibiotic identification
and redesign, translation may yet be the perfect solution to
antibiotic resistance.
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